This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fendly, B. M. Articles by Ullrich, A. Search for Related Content PubMed PubMed Citation Articles by Fendly, B. M. Articles by Ullrich, A.

Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/neu Gene Product

Departments of Medicinal and Analytical Chemistry [B. M. F., M. W.], Developmental Biology [R. M. H., A. U.], and Medicinal and Biomolecular Chemistry [M. T. L., M.A.N.], Genentech, Inc., South San Francisco, California 94080

High levels of expression of either the epidermal growth factor receptor or the receptor-like HER2/neu gene product p185^HER2 have been observed in a variety of human malignancies. Because of the association of this high level expression with certain human tumors, we have generated a panel of monoclonal antibodies specific for either the epidermal growth factor receptor or p185^HER2 to study their structure, function, and antigenic domains in the normal and neoplastic states. We used the epidermoid carcinoma line A431 to generate five monoclonal antibodies which immunoprecipitate the epidermal growth factor receptor. These monoclonal antibodies bind to the extracellular domain of the epidermal growth factor receptor and demonstrate variable effects on epidermal growth factor binding. We used a stably transfected NIH 3T3 cell line expressing the HER2/neu gene to produce and characterize 10 monoclonal antibodies which immunoprecipitate p185^HER2. These monoclonal antibodies bind to the extracellular domain of p185^HER2 and do not cross-react with the epidermal growth factor receptor. The characteristics and potential applications of these monoclonal antibodies will be discussed.

¹ To whom requests for reprints should be addressed, at Department of Medicinal and Analytical Chemistry, Genentech, Inc., 460 Point San Bruno Blvd., San Francisco, CA 94080.

Received 3/30/89. Revised 7/27/89. Revised 11/21/89. Accepted 12/ 4/89.

This article has been cited by other articles:

				J. Albanell, C. Montagut, E. T. Jones, L. Pronk, B. Mellado, J. Beech, P. Gascon, G. Zugmaier, M. Brewster, M. P. Saunders, et al. A Phase I Study of the Safety and Pharmacokinetics of the Combination of Pertuzumab (rhuMab 2C4) and Capecitabine in Patients with Advanced Solid Tumors Clin. Cancer Res., May 1, 2008; 14(9): 2726 - 2731. [Abstract] [Full Text] [PDF]

				C. A. Hudis Trastuzumab -- Mechanism of Action and Use in Clinical Practice N. Engl. J. Med., July 5, 2007; 357(1): 39 - 51. [Full Text] [PDF]

				S. D. Allen, J. T. Garrett, S. V. Rawale, A. L. Jones, G. Phillips, G. Forni, J. C. Morris, R. G. Oshima, and P. T. P. Kaumaya Peptide Vaccines of the HER-2/neu Dimerization Loop Are Effective in Inhibiting Mammary Tumor Growth In Vivo J. Immunol., July 1, 2007; 179(1): 472 - 482. [Abstract] [Full Text] [PDF]

				G. Niu and W. B. Carter Human Epidermal Growth Factor Receptor 2 Regulates Angiopoietin-2 Expression in Breast Cancer via AKT and Mitogen-Activated Protein Kinase Pathways Cancer Res., February 15, 2007; 67(4): 1487 - 1493. [Abstract] [Full Text] [PDF]

				F. Meric-Bernstam and M.-C. Hung Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy. Clin. Cancer Res., November 1, 2006; 12(21): 6326 - 6330. [Abstract] [Full Text] [PDF]

				K. Kimura, T. Sawada, M. Komatsu, M. Inoue, K. Muguruma, T. Nishihara, Y. Yamashita, N. Yamada, M. Ohira, and K. Hirakawa Antitumor Effect of Trastuzumab for Pancreatic Cancer with High HER-2 Expression and Enhancement of Effect by Combined Therapy with Gemcitabine. Clin. Cancer Res., August 15, 2006; 12(16): 4925 - 4932. [Abstract] [Full Text] [PDF]

				D. N. Krag, G. S. Shukla, G.-P. Shen, S. Pero, T. Ashikaga, S. Fuller, D. L. Weaver, S. Burdette-Radoux, and C. Thomas Selection of Tumor-binding Ligands in Cancer Patients with Phage Display Libraries. Cancer Res., August 1, 2006; 66(15): 7724 - 7733. [Abstract] [Full Text] [PDF]

				P. D. Vermeer, L. Panko, P. Karp, J. H. Lee, and J. Zabner Differentiation of human airway epithelia is dependent on erbB2 Am J Physiol Lung Cell Mol Physiol, August 1, 2006; 291(2): L175 - L180. [Abstract] [Full Text] [PDF]

				G. Orr, D. Hu, S. Ozcelik, L. K. Opresko, H. S. Wiley, and S. D. Colson Cholesterol Dictates the Freedom of EGF Receptors and HER2 in the Plane of the Membrane Biophys. J., August 1, 2005; 89(2): 1362 - 1373. [Abstract] [Full Text] [PDF]

				D. B. Agus, M. S. Gordon, C. Taylor, R. B. Natale, B. Karlan, D. S. Mendelson, M. F. Press, D. E. Allison, M. X. Sliwkowski, G. Lieberman, et al. Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer J. Clin. Oncol., April 10, 2005; 23(11): 2534 - 2543. [Abstract] [Full Text] [PDF]

				B. S. Hendriks, G. Orr, A. Wells, H. S. Wiley, and D. A. Lauffenburger Parsing ERK Activation Reveals Quantitatively Equivalent Contributions from Epidermal Growth Factor Receptor and HER2 in Human Mammary Epithelial Cells J. Biol. Chem., February 18, 2005; 280(7): 6157 - 6169. [Abstract] [Full Text] [PDF]

				P. Carter, L. Smith, and M. Ryan Identification and validation of cell surface antigens for antibody targeting in oncology Endocr. Relat. Cancer, December 1, 2004; 11(4): 659 - 687. [Abstract] [Full Text] [PDF]

				M. Schlapschy, H. Gruber, O. Gresch, C. Schafer, C. Renner, M. Pfreundschuh, and A. Skerra Functional humanization of an anti-CD30 Fab fragment for the immunotherapy of Hodgkin's lymphoma using an in vitro evolution approach Protein Eng. Des. Sel., December 1, 2004; 17(12): 847 - 860. [Abstract] [Full Text] [PDF]

				C. D. Austin, A. M. De Maziere, P. I. Pisacane, S. M. van Dijk, C. Eigenbrot, M. X. Sliwkowski, J. Klumperman, and R. H. Scheller Endocytosis and Sorting of ErbB2 and the Site of Action of Cancer Therapeutics Trastuzumab and Geldanamycin Mol. Biol. Cell, December 1, 2004; 15(12): 5268 - 5282. [Abstract] [Full Text] [PDF]

				C. D. Britten Targeting ErbB receptor signaling: A pan-ErbB approach to cancer Mol. Cancer Ther., October 1, 2004; 3(10): 1335 - 1342. [Abstract] [Full Text] [PDF]

				F. A. Fellouse, C. Wiesmann, and S. S. Sidhu Synthetic antibodies from a four-amino-acid code: A dominant role for tyrosine in antigen recognition PNAS, August 24, 2004; 101(34): 12467 - 12472. [Abstract] [Full Text] [PDF]

				A. A. Peden, E. Schonteich, J. Chun, J. R. Junutula, R. H. Scheller, and R. Prekeris The RCP-Rab11 Complex Regulates Endocytic Protein Sorting Mol. Biol. Cell, August 1, 2004; 15(8): 3530 - 3541. [Abstract] [Full Text] [PDF]

				J. G. Jackson, P. St. Clair, M. X. Sliwkowski, and M. G. Brattain Blockade of Epidermal Growth Factor- or Heregulin-Dependent ErbB2 Activation with the Anti-ErbB2 Monoclonal Antibody 2C4 Has Divergent Downstream Signaling and Growth Effects Cancer Res., April 1, 2004; 64(7): 2601 - 2609. [Abstract] [Full Text] [PDF]

				M. Gensler, M. Buschbeck, and A. Ullrich Negative Regulation of HER2 Signaling by the PEST-type Protein-tyrosine Phosphatase BDP1 J. Biol. Chem., March 26, 2004; 279(13): 12110 - 12116. [Abstract] [Full Text] [PDF]

				B. S. Hendriks, H. S. Wiley, and D. Lauffenburger HER2-Mediated Effects on EGFR Endosomal Sorting: Analysis of Biophysical Mechanisms Biophys. J., October 1, 2003; 85(4): 2732 - 2745. [Abstract] [Full Text] [PDF]

				B. S. Hendriks, L. K. Opresko, H. S. Wiley, and D. Lauffenburger Quantitative Analysis of HER2-mediated Effects on HER2 and Epidermal Growth Factor Receptor Endocytosis: DISTRIBUTION OF HOMO- AND HETERODIMERS DEPENDS ON RELATIVE HER2 LEVELS J. Biol. Chem., June 20, 2003; 278(26): 23343 - 23351. [Abstract] [Full Text] [PDF]

				B. S. Hendriks, L. K. Opresko, H. S. Wiley, and D. Lauffenburger Coregulation of Epidermal Growth Factor Receptor/Human Epidermal Growth Factor Receptor 2 (HER2) Levels and Locations: Quantitative Analysis of HER2 Overexpression Effects Cancer Res., March 1, 2003; 63(5): 1130 - 1137. [Abstract] [Full Text] [PDF]

				D. Sachdev, S.-L. Li, J. S. Hartell, Y. Fujita-Yamaguchi, J. S. Miller, and D. Yee A Chimeric Humanized Single-Chain Antibody against the Type I Insulin-like Growth Factor (IGF) Receptor Renders Breast Cancer Cells Refractory to the Mitogenic Effects of IGF-I Cancer Res., February 1, 2003; 63(3): 627 - 635. [Abstract] [Full Text] [PDF]

				M. A. Bookman, K. M. Darcy, D. Clarke-Pearson, R. A. Boothby, and I. R. Horowitz Evaluation of Monoclonal Humanized Anti-HER2 Antibody, Trastuzumab, in Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Carcinoma With Overexpression of HER2: A Phase II Trial of the Gynecologic Oncology Group J. Clin. Oncol., January 15, 2003; 21(2): 283 - 290. [Abstract] [Full Text] [PDF]

				J.-L. Merlin, M. Barberi-Heyob, and N. Bachmann In vitro comparative evaluation of trastuzumab (Herceptin(R)) combined with paclitaxel (Taxol(R)) or docetaxel (Taxotere(R)) in HER2-expressing human breast cancer cell lines Ann. Onc., November 1, 2002; 13(11): 1743 - 1748. [Abstract] [Full Text] [PDF]

				N. Mendoza, G. L. Phillips, J. Silva, R. Schwall, and D. Wickramasinghe Inhibition of Ligand-mediated HER2 Activation in Androgen-independent Prostate Cancer Cancer Res., October 1, 2002; 62(19): 5485 - 5488. [Abstract] [Full Text] [PDF]

				A. E. Frankel New HER2-directed Therapies for Breast Cancer.: Commentary re: C. I. Spiridon et al., Targeting Multiple Her-2 Epitopes with Monoclonal Antibodies Results in Improved Antigrowth Activity. Clin. Cancer Res., 8: 1720-1730, 2002. Clin. Cancer Res., June 1, 2002; 8(6): 1699 - 1701. [Full Text] [PDF]

				C. I. Spiridon, M.-A. Ghetie, J. Uhr, R. Marches, J.-L. Li, G.-L. Shen, and E. S. Vitetta Targeting Multiple Her-2 Epitopes with Monoclonal Antibodies Results in Improved Antigrowth Activity of a Human Breast Cancer Cell Line in Vitro and in Vivo Clin. Cancer Res., June 1, 2002; 8(6): 1720 - 1730. [Abstract] [Full Text] [PDF]

				S. C. Pero, L. Oligino, R. J. Daly, A. L. Soden, C. Liu, P. P. Roller, P. Li, and D. N. Krag Identification of Novel Non-phosphorylated Ligands, Which Bind Selectively to the SH2 Domain of Grb7 J. Biol. Chem., March 29, 2002; 277(14): 11918 - 11926. [Abstract] [Full Text] [PDF]

				M. A. Molina, R. Saez, E. E. Ramsey, M.-J. Garcia-Barchino, F. Rojo, A. J. Evans, J. Albanell, E. J. Keenan, A. Lluch, J. Garcia-Conde, et al. NH2-terminal Truncated HER-2 Protein but not Full-Length Receptor Is Associated with Nodal Metastasis in Human Breast Cancer Clin. Cancer Res., February 1, 2002; 8(2): 347 - 353. [Abstract] [Full Text] [PDF]

				M. A. Molina, J. Codony-Servat, J. Albanell, F. Rojo, J. Arribas, and J. Baselga Trastuzumab (Herceptin), a Humanized Anti-HER2 Receptor Monoclonal Antibody, Inhibits Basal and Activated HER2 Ectodomain Cleavage in Breast Cancer Cells Cancer Res., June 1, 2001; 61(12): 4744 - 4749. [Abstract] [Full Text] [PDF]

				J. Mendelsohn Use of an Antibody to Target Geldanamycin J Natl Cancer Inst, October 4, 2000; 92(19): 1549 - 1551. [Full Text] [PDF]

				R. Lammers, M. M. Lerch, and A. Ullrich The Carboxyl-terminal Tyrosine Residue of Protein-tyrosine Phosphatase alpha Mediates Association with Focal Adhesion Plaques J. Biol. Chem., February 4, 2000; 275(5): 3391 - 3396. [Abstract] [Full Text] [PDF]

				R. J. Pietras, J. C. Poen, D. Gallardo, P. N. Wongvipat, H. J. Lee, and D. J. Slamon Monoclonal Antibody to HER-2/neuReceptor Modulates Repair of Radiation-induced DNA Damage and Enhances Radiosensitivity of Human Breast Cancer Cells Overexpressing This Oncogene Cancer Res., March 1, 1999; 59(6): 1347 - 1355. [Abstract] [Full Text] [PDF]

				G. Schaefer, R. W. Akita, and M. X. Sliwkowski A Discrete Three-amino Acid Segment (LVI) at the C-terminal End of Kinase-impaired ErbB3 Is Required for Transactivation of ErbB2 J. Biol. Chem., January 8, 1999; 274(2): 859 - 866. [Abstract] [Full Text] [PDF]

				J. T. Jones, M. D. Ballinger, P. I. Pisacane, J. A. Lofgren, V. D. Fitzpatrick, W. J. Fairbrother, J. A. Wells, and M. X. Sliwkowski Binding Interaction of the Heregulinbeta egf Domain with ErbB3 and ErbB4 Receptors Assessed by Alanine Scanning Mutagenesis J. Biol. Chem., May 8, 1998; 273(19): 11667 - 11674. [Abstract] [Full Text] [PDF]

				C. Hopf and W. Hoch Dimerization of the Muscle-specific Kinase Induces Tyrosine Phosphorylation of Acetylcholine Receptors and Their Aggregation on the Surface of Myotubes J. Biol. Chem., March 13, 1998; 273(11): 6467 - 6473. [Abstract] [Full Text] [PDF]

				J. Zou, D. H. Presky, C.-Y. Wu, and U. Gubler Differential Associations between the Cytoplasmic Regions of the Interleukin-12 Receptor Subunits beta 1 and beta 2 and JAK Kinases J. Biol. Chem., February 28, 1997; 272(9): 6073 - 6077. [Abstract] [Full Text] [PDF]

				A. Kharitonenkov, Jür. Schnekenburger, Z. Chen, P. Knyazev, S. Ali, E. Zwick, M. White, and A. Ullrich Adapter Function of Protein-tyrosine Phosphatase 1D in Insulin Receptor/Insulin Receptor Substrate-1 Interaction J. Biol. Chem., December 8, 1995; 270(49): 29189 - 29193. [Abstract] [Full Text] [PDF]

				N. P. H. Møller, K. B. Møller, R. Lammers, A. Kharitonenkov, E. Hoppe, F. C. Wiberg, I. Sures, and A. Ullrich Selective Down-regulation of the Insulin Receptor Signal by Protein-tyrosine Phosphatases alpha and [IMAGE] J. Biol. Chem., September 29, 1995; 270(39): 23126 - 23131. [Abstract] [Full Text] [PDF]

				K. Seedorf, M. Shearman, and A. Ullrich Rapid and Long Term Effects of Protein Kinase C on Receptor Tyrosine Kinase Phosphorylation and Degradation J. Biol. Chem., August 11, 1995; 270(32): 18953 - 18960. [Abstract] [Full Text] [PDF]

				K. L.:I. Carraway, S. P. Soltoff, and L. C. Cantley Heregulin Stimulates Mitogenesis and Phosphatidylinositol 3-Kinase in Mouse Fibroblasts Transfected with erbB2/neu and erbB3 J. Biol. Chem., March 31, 1995; 270(13): 7111 - 7116. [Abstract] [Full Text] [PDF]

				A. Chantry and A. Chantry The Kinase Domain and Membrane Localization Determine Intracellular Interactions between Epidermal Growth Factor Receptors J. Biol. Chem., February 17, 1995; 270(7): 3068 - 3073. [Abstract] [Full Text] [PDF]

				R Lupu, R Colomer, G Zugmaier, J Sarup, M Shepard, D Slamon, and M. Lippman Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2 Science, September 28, 1990; 249(4976): 1552 - 1555. [Abstract] [PDF]

				A. Gomez, C. Wellbrock, H. Gutbrod, N. Dimitrijevic, and M. Schartl Ligand-independent Dimerization and Activation of the Oncogenic Xmrk Receptor by Two Mutations in the Extracellular Domain J. Biol. Chem., January 26, 2001; 276(5): 3333 - 3340. [Abstract] [Full Text] [PDF]